Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 54.03

-1.2%

3:42 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (8155)	4/21/2003 3:09:09 PM
From: keokalani'nui	Read Replies (1) of 52153

I post this here only because I believe many bfreaks are interested in these results, and the company has not given much warning. Near term options clearly indicate belief in success, and stock is acting ho-hum. Neurocrine Biosciences Announces Webcast and Conference Call Monday April 21, 2:00 pm ET Company to Present Results From Phase III Clinical Trial With Indiplon in 200 Subjects With Primary (Chronic) Insomnia SAN DIEGO, April 21 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX - News) announced today that the Company will host a Conference Call and Webcast to report on the Phase III clinical trial results with indiplon for Primary (Chronic) Insomnia. The Conference Call and Webcast will be held today, Monday, April 21, 2003 at 4:30 PM Eastern Daylight Time (EDT)/1:30 PM Pacific Daylight Time (PDT). Participants may access the live Conference Call by dialing 1-800-903-0247 (US) or 785-832-1077 (International) and using the access code of NBIX or Neurocrine. The call can also be accessed via the Webcast through the Company's website at www.neurocrine.com or through a link provided by PR Newswire at firstcallevents.com .

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next